Back

Incidence, definitions and outcomes of anthracycline induced subclinical and clinical left ventricular dysfunction: a systematic review and meta-analysis

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Cardiomyopathy in cancer patients: prevalence, risk assessment, imaging, and prevention Cardio-Oncology ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Naba Farooqui

Mayo Clinic Hospital-Rochester, Rochester (United States of America)

5 More presentations in this session

Presentation thumbnail
Prospective screening and proposed treatment algorithm for immune checkpoint inhibitor induced myositis in neoadjuvant-treated rectal cancer patients: data from the phase II CHINOREC trial
Doctor R. Zirnbauer (Vienna, AT)
Abstract Slides Video
Presentation thumbnail
Cardioprotective role of statins in breast cancer patients treated with anthracyclines and/or trastuzumab: a systematic review and meta-analysis
Doctor S. Lingamsetty (Khammam, IN)
Abstract Slides Video
Presentation thumbnail
Anthracycline-induced arterial toxicity: structural and inflammatory assessments in non-human primates and lymphoma patients using 18F-FDG positron emission tomography
Doctor S. Rankin (Glasgow, GB)
Abstract Slides Video
Presentation thumbnail
Validation of the HFA-ICOS risk assessment tool with real-world data from a prospective cohort of breast cancer patients in treatment with anthracyclines and trastuzumab
Doctor N. Espinola-Zavaleta (Mexico City, MX) Doctor E. Guerra (Tlalpan, MX)
Abstract Slides Video
Presentation thumbnail
Comparison of two anthracycline regimens for treatment of breast cancer and the incidence of cardiac injury
Doctor N. Osataphan (Chiang Mai, TH)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiomyopathy in cancer patients: prevalence, risk assessment, imaging, and prevention

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Is there an association of anthracyclines with HFrEF and/or HFpEF in patients treated for breast cancer or lymphoma after 30 years of follow-up? Insights from the Rochester epidemiology project
thumbnail
Congress Presentation
New onset of left ventricular dysfunction and diastolic dysfunction are uncommon in patients with her2+ breast cancer after completion of cancer therapy.
thumbnail
Congress Presentation
Comparison of two anthracycline regimens for treatment of breast cancer and the incidence of cardiac injury

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources